Argos Therapeutics, Inc. (ARGS) was a biopharmaceutical company focused on the development of immunotherapy treatments for cancer and infectious diseases. The company's product candidates were based on its Arcelis technology platform, which is designed to personalize immunotherapies by using a patient's own dendritic cells to target specific antigens.
Argos Therapeutics' lead product candidate was called AGS-003, which was being developed as a treatment for metastatic renal cell carcinoma. The company also had a pipeline of other product candidates in various stages of development for cancer and infectious diseases.
Argos Therapeutics was founded in 1997 and was headquartered in Durham, North Carolina. However, in 2019, the company filed for bankruptcy and subsequently sold its assets to an investment firm. As a result, Argos Therapeutics is no longer a publicly traded company.
Argos Therapeutics, Inc. (ARGS) was a biopharmaceutical company focused on the development of immunotherapy treatments for cancer and infectious diseases. The company's product candidates were based on its Arcelis technology platform, which is designed to personalize immunotherapies by using a patient's own dendritic cells to target specific antigens.